Enanta Pharmaceuticals (ENTA) EBITDA (2012 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly EBITDA came in at -$11.9 million in Q1 2026, up 51.68% YoY from -$7.8 million in Q1 2025, and down 5.32% on a QoQ basis from -$11.3 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) EBITDA (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 15 years of EBITDA data on file, last reported at -$11.9 million in Q1 2026.
- Quarterly EBITDA rose 51.68% year-over-year to -$11.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$60.4 million (up 40.86% YoY) and the FY2025 annual result came in at -$85.3 million, up 29.86% from the prior year.
- EBITDA fell to -$11.9 million in Q1 2026, from -$11.3 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$11.3 million in Q4 2025 to a low of -$39.5 million in Q1 2023.
- A 5-year average of -$27.1 million and a median of -$29.9 million in 2024 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2023 — EBITDA fell 16.56% — and 2025, when it surged 52.2%.
- Tracing ENTA's EBITDA over 5 years: stood at -$30.0 million in 2022, then retreated by 16.24% to -$34.9 million in 2023, then soared by 32.51% to -$23.5 million in 2024, then surged by 52.2% to -$11.3 million in 2025, then retreated by 5.32% to -$11.9 million in 2026.
- The last three EBITDA figures came in at -$11.9 million (Q1 2026), -$11.3 million (Q4 2025), and -$18.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Enanta Pharmaceuticals | 383.29 Mn | 193.78 Mn | - | -17.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.24 Mn |
| Mar 31, 2026 | -11.85 Mn |
| Dec 31, 2025 | -11.25 Mn |
| Sep 30, 2025 | -18.39 Mn |
| Jun 30, 2025 | -18.89 Mn |
| Mar 31, 2025 | -24.53 Mn |
| Dec 31, 2024 | -23.54 Mn |
| Sep 30, 2024 | -29.85 Mn |
| Jun 30, 2024 | -24.19 Mn |
| Mar 31, 2024 | -32.77 Mn |
| Dec 31, 2023 | -34.89 Mn |
| Sep 30, 2023 | -31.03 Mn |
| Jun 30, 2023 | -36.71 Mn |
| Mar 31, 2023 | -39.45 Mn |
| Dec 31, 2022 | -30.01 Mn |
| Sep 30, 2022 | -27.05 Mn |
| Jun 30, 2022 | -32.54 Mn |
| Mar 31, 2022 | -33.85 Mn |
| Dec 31, 2021 | -30.41 Mn |
| Sep 30, 2021 | -33.73 Mn |